DEA Archived Press Releases

Press Releases before January 20, 2025
10 Results - Showing 1 to 10
PRESS RELEASE

DEA Recognizes National Fentanyl Prevention and Awareness Day

WASHINGTON – The U.S. Drug Enforcement Administration will recognize National Fentanyl Prevention and Awareness Day on Wednesday, August 21 with extended DEA Museum hours from 6 a.m. to 6 p.m. The Faces of Fentanyl exhibit is one of the museum’s featured exhibits, and commemorates the lives lost to fentanyl. More...
PRESS RELEASE

DEA Issues Letter to E-Commerce Companies on the Sale of Pill Presses Used to Make Fentanyl Pills

WASHINGTON – The U.S. Drug Enforcement Administration today issued a letter to e-commerce companies regarding the sale of pill presses. As regulated entities under the Controlled Substances Act (CSA), e-commerce platforms are generally required to comply with CSA recordkeeping, identification, and reporting requirements on the distribution, importation, and exportation of...
PRESS RELEASE

DEA Announces Settlement with Morris & Dickson Co., LLC

WASHINGTON, D.C. – The U.S. Drug Enforcement Administration announced today a settlement with pharmaceutical distributor Morris & Dickson Co., LLC for failing to maintain effective controls against diversion of controlled substances, including failure to report to DEA thousands of unusually large orders of oxycodone and hydrocodone. Morris & Dickson, which...
PRESS RELEASE

DEA Encourages Communities to Make Every Day Take Back Day

WASHINGTON – The U.S. Drug Enforcement Administration has launched a new campaign encouraging the public to make Every Day Take Back Day by utilizing year-round collection sites to dispose of unneeded and unwanted medications. For more than a decade, DEA has worked with state and local law enforcement partners to...
PRESS RELEASE

13 Additional Defendants Charged in Fentanyl Distribution Network that Spanned from California to D.C.

WASHINGTON – Federal and local law enforcement announced the arrests of 11 more alleged members of a fentanyl drug distribution network responsible for bringing hundreds of thousands of fake Oxycodone (M30) pills from California to D.C. Today's announcement was made by DEA Administrator Anne Milgram, U.S. Attorney Matthew M. Graves...
PRESS RELEASE

DEA Recognizes National Fentanyl Prevention and Awareness Day with Extended Hours for the Faces of Fentanyl Exhibit

WASHINGTON – The Drug Enforcement Administration recognizes National Fentanyl Prevention and Awareness Day by joining the dedicated voices who continue to raise awareness in an effort to prevent the fentanyl poisonings devastating families across the country. On Monday, August 21 the DEA Museum will open with extended hours from 6...
PRESS RELEASE

DEA Hosts Public Listening Sessions on Telemedicine Regulations

WASHINGTON – The Drug Enforcement Administration will host public listening sessions to receive comments from healthcare practitioners, experts, advocates, patients, and other members of the public to inform DEA’s regulations on prescribing controlled substances via telemedicine. The listening sessions will be held in person and livestreamed with remote participation available...
PRESS RELEASE

DEA Recognizes National Fentanyl Awareness Day

WASHINGTON – DEA is proud to join “Song for Charlie” and many of our valued law enforcement, public health, and non-profit partners in recognizing National Fentanyl Awareness Day. Tomorrow represents an important opportunity to remember the victims of fentanyl poisoning and educate people in our communities about the deadly threat...
PRESS RELEASE

DEA 2020 Year in Review: Combatting Serious Drug-Related Threats During the Pandemic

WASHINGTON – With the unprecedented worldwide health emergency brought on by COVID-19, last year was filled with new challenges and increased risks. While much of the world focused on combating the pandemic, DEA continued to implement initiatives to combat violent drug traffickers who were intent on flooding cities and rural...
PRESS RELEASE

Omnicare Inc. agrees to pay more than $15 million to resolve allegations it improperly dispensed narcotics at long-term care facilities

WASHINGTON – Omnicare Inc., a subsidiary of CVS Health and a leading provider of pharmacy services to long-term care facilities, has agreed to pay the United States a $15.3 million civil penalty to resolve allegations that it violated federal law by allowing opioids and other controlled substances to be dispensed...